Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

Abstract:

:Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/microl/h pre- and 13.3 cells/microl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8-20 days) and day 13 (range 7-77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.

journal_name

Bone Marrow Transplant

authors

Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

doi

10.1038/bmt.2009.119

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

39-47

issue

1

eissn

0268-3369

issn

1476-5365

pii

bmt2009119

journal_volume

45

pub_type

临床试验,杂志文章,多中心研究
  • Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.

    abstract::Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702356

    authors: Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

    更新日期:2000-05-01 00:00:00

  • Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.

    abstract::To control disease before allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory AML, we used clofarabine cytoreduction. Seventeen patients received clofarabine 30-40  mg/m(2) i.v. daily for 5 days with plans to initiate conditioning during the nadir, 14 days later. Bone marrow biopsy 12 days afte...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.32

    authors: Locke FL,Artz A,Rich E,Zhang Y,van Besien K,Stock W

    更新日期:2010-12-01 00:00:00

  • Thyroid function after autologous bone marrow transplantation.

    abstract::Thyroid function was prospectively analysed in 111 consecutive patients in relation to autologous bone marrow transplantation (ABMT). Median follow-up time was 12 (range 3-60) months. As part of the conditioning treatment 58 patients had received total body irradiation (TBI) as a single dose of 7.5 Gy (dose rate 0.15 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Carlson K,Lönnerholm G,Smedmyr B,Oberg G,Simonsson B

    更新日期:1992-08-01 00:00:00

  • Immunomagnetic depletion of CD6+ cells from bone marrow and peripheral blood.

    abstract::Depletion of donor CD6+ cells in HLA-identical allogeneic bone marrow transplantation has been reported to reduce graft-versus-host disease without interfering with engraftment. We have established an immunomagnetic cell separation technique capable of producing a 2-3 log depletion of CD6+ cells. Median recovery of CD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Egeland T,Albrechtsen D,Martin PJ,Hansen JA

    更新日期:1990-03-01 00:00:00

  • Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation.

    abstract::To examine the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery after high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT), 20 patients with hematologic malignancies were divided into two groups. One group was given G-CSF at a daily dose of 50 micrograms/...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Shimazaki C,Oku N,Uchiyama H,Yamagata N,Tatsumi T,Hirata T,Ashihara E,Okawa K,Goto H,Inaba T

    更新日期:1994-03-01 00:00:00

  • Underlying coronary artery disease and successful bone marrow transplantation: a case report.

    abstract::The cardiovascular risk of concurrent coronary artery disease in patients undergoing bone marrow transplantation (BMT) is not well known. We present a case of a 32-year-old male Hodgkin's disease patient with prior chemotherapy and radiotherapy, who underwent autologous BMT. His underlying single vessel coronary arter...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schechter D,Drakos P,Nagler A

    更新日期:1994-05-01 00:00:00

  • Quality of life and behavioral adjustment after pediatric bone marrow transplantation.

    abstract::The purpose of this study was two-fold: to describe the quality of life and behavioral adjustment of survivors of pediatric bone marrow transplantation (BMT) prior to and 6 months post-BMT; and, to identify correlates of survivors' quality of life and behavioral adjustment. Participants were 26 children and adolescent...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702527

    authors: Barrera M,Boyd-Pringle LA,Sumbler K,Saunders F

    更新日期:2000-08-01 00:00:00

  • Alefacept treatment for refractory chronic extensive GVHD.

    abstract::Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its effect in acute steroid-resistant/dependent GVHD. In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD). Twelve patients were included in this study; of...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.324

    authors: Shapira MY,Abdul-Hai A,Resnick IB,Bitan M,Tsirigotis P,Aker M,Gesundheit B,Slavin S,Or R

    更新日期:2009-02-01 00:00:00

  • Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries.

    abstract::Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703954

    authors: Giné E,Rovira M,Real I,Burrel M,Montaña J,Carreras E,Montserrat E

    更新日期:2003-05-01 00:00:00

  • Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.

    abstract::There is a known increased risk of skin cancer in the adult population after hematopoietic stem cell transplantation (HSCT). However, late dermatologic effects that children may experience after HSCT have not been well described. The primary objective of this study was to characterize nevi and skin cancers affecting c...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2017.57

    authors: Song JS,London WB,Hawryluk EB,Guo D,Sridharan M,Fisher DE,Lehmann LE,Duncan CN,Huang JT

    更新日期:2017-07-01 00:00:00

  • High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

    abstract::Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2012.14

    authors: Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

    更新日期:2012-10-01 00:00:00

  • Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

    abstract::In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2008.165

    authors: Cheuk DK,Mok AS,Lee AC,Chiang AK,Ha SY,Lau YL,Chan GC

    更新日期:2008-09-01 00:00:00

  • Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy.

    abstract::Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM) ranges in severity from a self-limiting to a fatal disorder. There is no specific therapy for this condition to date. We have previously described a simple clinical grading system (grade 0-4) for BMT-TM; patients with grade 3-4 BMT-TM do poorly. A p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zeigler ZR,Shadduck RK,Nath R,Andrews DF 3rd

    更新日期:1996-01-01 00:00:00

  • GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.

    abstract::To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700814

    authors: Watanabe T,Dave B,Heimann DG,Lethaby E,Kessinger A,Talmadge JE

    更新日期:1997-06-01 00:00:00

  • The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.

    abstract::At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchos...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701525

    authors: Humar A,O'Rourke K,Lipton J,Messner H,Meharchand J,Mahony J,Walker I,Wasi P,McGeer A,Moussa G,Chua R,Mazzulli T

    更新日期:1999-01-01 00:00:00

  • Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.

    abstract::Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma...

    journal_title:Bone marrow transplantation

    pub_type: 信件

    doi:10.1038/s41409-018-0112-x

    authors: Pandit A,Leblebjian H,Hammond SP,Laubach JP,Richardson PG,Baden LR,Marty FM,Issa NC

    更新日期:2018-07-01 00:00:00

  • N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

    abstract::Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704143

    authors: Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

    更新日期:2003-08-01 00:00:00

  • Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.

    abstract::Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701403

    authors: Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

    更新日期:1998-10-01 00:00:00

  • The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.

    abstract::Recent studies from this laboratory have shown that unmanipulated, MHC-mismatched allogeneic bone marrow (BM) engrafts and produces complete allogeneic chimerism when administered to recipient mice 8 days following lethal irradiation and reconstitution with T cell-depleted (TCD) syngeneic bone marrow. Host lymphopoiet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chester CH,Sykes M,Sachs DH

    更新日期:1989-03-01 00:00:00

  • Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.

    abstract::To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

    更新日期:1988-01-01 00:00:00

  • Randomized phase III study of granulocyte transfusions in neutropenic patients.

    abstract::Despite antibiotics, antifungals and haematopoietic growth factors, infections remain a major threat to neutropenic patients. To determine the role of granulocyte transfusions (GTs) in anti-infective therapy during neutropenia, GT administration was randomized in 74 adults with haematological or malignant diseases, fe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2008.237

    authors: Seidel MG,Peters C,Wacker A,Northoff H,Moog R,Boehme A,Silling G,Grimminger W,Einsele H

    更新日期:2008-11-01 00:00:00

  • Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis.

    abstract::Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701380

    authors: Bischoff ME,Blau W,Wagner T,Wagenmann W,Dörner O,Basara N,Fauser AA

    更新日期:1998-09-01 00:00:00

  • Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.

    abstract::Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

    更新日期:1996-11-01 00:00:00

  • A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions.

    abstract::The extant literature documents burden among caregivers of patients undergoing a hematopoietic stem cell transplantation (HSCT), but little is known about the burden of caregivers of patients receiving outpatient and homebound HSCTs. This scoping study sought to evaluate what is known about the burden of the increasin...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2016.164

    authors: Applebaum AJ,Bevans M,Son T,Evans K,Hernandez M,Giralt S,DuHamel K

    更新日期:2016-11-01 00:00:00

  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract::Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1700628

    authors: Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期:1997-02-01 00:00:00

  • Evaluating the association between histological manifestations of cord colitis syndrome with GVHD.

    abstract::Cord colitis syndrome (CCS) is a recently proposed clinical entity characterized by a persistent diarrheal illness after cord blood transplantation (CBT), which is not caused by GVHD or CMV colitis. CCS is histologically characterized by chronic active colitis with granulomatous inflammation and Paneth cell metaplasia...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.44

    authors: Shimoji S,Kato K,Eriguchi Y,Takenaka K,Iwasaki H,Miyamoto T,Oda Y,Akashi K,Teshima T

    更新日期:2013-09-01 00:00:00

  • High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.

    abstract::One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolate...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705799

    authors: Mehta J,Singhal S

    更新日期:2007-12-01 00:00:00

  • Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants.

    abstract::Non-compliance has received significant attention in medicine, yet few studies have examined its correlates in autologous hematopoietic SCT (AHSCT) patients. This study examined predictors of non-compliance in a sample of 151 AHSCT patients treated in an outpatient setting. Before AHSCT, participants completed a valid...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2011.129

    authors: Mumby PB,Hurley C,Samsi M,Thilges S,Parthasarathy M,Stiff PJ

    更新日期:2012-04-01 00:00:00

  • Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose.

    abstract::Fourteen children with high risk leukaemia received allogeneic bone marrow transplants from HLA-identical MLC-compatible sibling donors. All bone marrows were T cell depleted and a T cell addback was prepared from the donor's peripheral blood so that the mean total number of CD3+ cells given was 2.6 (1.0-4.1) x 10(5)/...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Potter MN,Pamphilon DH,Cornish JM,Oakhill A

    更新日期:1991-11-01 00:00:00

  • Human-ovine xenogenic transplantation of stem cells in utero.

    abstract::The preimmune status of the early gestational age fetus provides a permissive environment that bypasses the immunological barrier and permits the engraftment and expression of hemopoietic stem cells (HSC). We used in utero approach to establish long term (greater than 2 years) engraftment and expression of human fetal...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zanjani ED,Pallavacini MG,Ascensao JL,Flake AW,Harrison MR,Tavassoli M

    更新日期:1992-01-01 00:00:00